EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
Background: Cirrhosis is a major cause of mortality and morbidity worldwide. It is also a frequent cause of hospital admissions. The objective of this study was to determine the efficacy of rifaximin and lactulose versus lactulose alone for the treatment of hepatic encephalopathy. Material & M...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Gomal Medical College, D.I.Khan, Pakistan
2016-12-01
|
| Series: | Gomal Journal of Medical Sciences |
| Subjects: | |
| Online Access: | http://gjms.com.pk/ojs24/index.php/gjms/article/view/1381 |
| _version_ | 1818995792744022016 |
|---|---|
| author | Hafsa Habib Dur-e- Nayab Zafar Hayat Shahid Jamil Habibullah Khan |
| author_facet | Hafsa Habib Dur-e- Nayab Zafar Hayat Shahid Jamil Habibullah Khan |
| author_sort | Hafsa Habib |
| collection | DOAJ |
| description | Background: Cirrhosis is a major cause of mortality and morbidity worldwide. It is also a frequent cause of hospital admissions. The objective of this study was to determine the efficacy of rifaximin and lactulose versus lactulose alone for the treatment of hepatic encephalopathy.
Material & Methods: This randomized controlled trial was conducted at Medical Unit A, Khyber Teaching Hospital, Peshawar, Pakistan. Duration of the study was six months in which a total of 122 patients were observed with 61 patients in each group. Consecutive, non-probability sampling technique was used for sample collection.
Results: Our study shows that mean age of the patients in Group A (rifaximin plus lactulose) was 50±2.31 years, while mean age of the patients in Group B (lactulose alone) was 52±2.78 years. In Group A 48% patients were males and 52% patients females while in Group B 45% patients were males and 55% females. Regarding the efficacy, rifaximin plus lactulose was effective in 45(74%) patients while lactulose alone was effective in 32(53%) patients with hepatic encephalopathy.
Conclusion: Lactulose plus rifaximin orally is more effective than lactulose alone in the treatment of acute hepatic encephalopathy. |
| first_indexed | 2024-12-20T21:19:29Z |
| format | Article |
| id | doaj.art-7767fd61edf143d8bfe23d9625620e21 |
| institution | Directory Open Access Journal |
| issn | 1819-7973 1997-2067 |
| language | English |
| last_indexed | 2024-12-20T21:19:29Z |
| publishDate | 2016-12-01 |
| publisher | Gomal Medical College, D.I.Khan, Pakistan |
| record_format | Article |
| series | Gomal Journal of Medical Sciences |
| spelling | doaj.art-7767fd61edf143d8bfe23d9625620e212022-12-21T19:26:19ZengGomal Medical College, D.I.Khan, PakistanGomal Journal of Medical Sciences1819-79731997-20672016-12-01141866EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSISHafsa Habib0Dur-e- Nayab1Zafar Hayat2Shahid Jamil3Habibullah Khan4Department of Medicine, Khyber Teaching Hospital, PeshawarDepartment of Medicine, Khyber Teaching Hospital, PeshawarDepartment of Medicine, Khyber Teaching Hospital, PeshawarDepartment of Medicine, Khyber Teaching Hospital, PeshawarDepartment of Medicine, Gomal Medical College, D.I.KhanBackground: Cirrhosis is a major cause of mortality and morbidity worldwide. It is also a frequent cause of hospital admissions. The objective of this study was to determine the efficacy of rifaximin and lactulose versus lactulose alone for the treatment of hepatic encephalopathy. Material & Methods: This randomized controlled trial was conducted at Medical Unit A, Khyber Teaching Hospital, Peshawar, Pakistan. Duration of the study was six months in which a total of 122 patients were observed with 61 patients in each group. Consecutive, non-probability sampling technique was used for sample collection. Results: Our study shows that mean age of the patients in Group A (rifaximin plus lactulose) was 50±2.31 years, while mean age of the patients in Group B (lactulose alone) was 52±2.78 years. In Group A 48% patients were males and 52% patients females while in Group B 45% patients were males and 55% females. Regarding the efficacy, rifaximin plus lactulose was effective in 45(74%) patients while lactulose alone was effective in 32(53%) patients with hepatic encephalopathy. Conclusion: Lactulose plus rifaximin orally is more effective than lactulose alone in the treatment of acute hepatic encephalopathy.http://gjms.com.pk/ojs24/index.php/gjms/article/view/1381liver cirrhosisrifaximinlactulosehepatic encephalopathy. |
| spellingShingle | Hafsa Habib Dur-e- Nayab Zafar Hayat Shahid Jamil Habibullah Khan EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS Gomal Journal of Medical Sciences liver cirrhosis rifaximin lactulose hepatic encephalopathy. |
| title | EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS |
| title_full | EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS |
| title_fullStr | EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS |
| title_full_unstemmed | EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS |
| title_short | EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS |
| title_sort | evaluation of efficacy of rifaximin in the treatment of hepatic encephalopathy in patients with cirrhosis |
| topic | liver cirrhosis rifaximin lactulose hepatic encephalopathy. |
| url | http://gjms.com.pk/ojs24/index.php/gjms/article/view/1381 |
| work_keys_str_mv | AT hafsahabib evaluationofefficacyofrifaximininthetreatmentofhepaticencephalopathyinpatientswithcirrhosis AT durenayab evaluationofefficacyofrifaximininthetreatmentofhepaticencephalopathyinpatientswithcirrhosis AT zafarhayat evaluationofefficacyofrifaximininthetreatmentofhepaticencephalopathyinpatientswithcirrhosis AT shahidjamil evaluationofefficacyofrifaximininthetreatmentofhepaticencephalopathyinpatientswithcirrhosis AT habibullahkhan evaluationofefficacyofrifaximininthetreatmentofhepaticencephalopathyinpatientswithcirrhosis |